Login to Your Account



A Win for Cancer Vaccines (Finally!)

Biovest's BiovaxID Improves Survival in Phase III NHL Trial

By Trista Morrison


Friday, July 18, 2008
Biovest International Inc. said cancer vaccine BiovaxID (personalized anti-idiotype vaccine) met its primary endpoint of significantly improving disease-free survival in a multicenter, randomized, controlled Phase III trial of patients with indolent follicular non-Hodgkin's lymphoma (NHL). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription